T he M2 isoform of pyruvate kinase, highly expressed in tumor cells, is known to engage a feed forward loop with the glycolysis master transcription factor HIF-1a. Gao and co-authors recently showed that dimeric PKM2 localizes to the nucleus in highly proliferating cancer cells, where it regulates in vivo growth by acting as a protein kinase and directly activating STAT3. STAT3 is therefore a novel player of the PKM2/HIF-1a feedback loop, since HIFinduced PKM2 activates STAT3 that in turn induces HIF-1a expression. These findings have profound implications for understanding the complex connections between gene regulation, metabolism, survival and proliferation in cancer.
Pyruvate kinase (PK) catalyzes the penultimate step of glycolysis by transferring phosphate from phosphoenolpyruvate (PEP) to ADP to generate ATP and pyruvate, which can then be converted in either lactate or acetyl-CoA to enter the TCA cycle. Of the four known isoforms, PKM1 and PKM2 derive from an alternative splicing of the same pkm2 gene. 1 PKM2 is highly expressed in embryonal cells and in tumors, and its prevalent expression in cancer cells has been linked to lower O 2 consumption and higher lactate secretion and glucose intake. The switch to the PKM2 isoform, observed in tumors of different origin, 2, 3 was shown to be essential for both the "Warburg" effect and proliferation of cancer cells. 4, 5 The main feature distinguishing PKM2 from the PKM1 isoform is the fact that its pyruvate kinase activity is subject to multiple layers of regulation. PKM2 can exist as a tetramer, which is enzymatically active, or as an inactive dimer. Interestingly, tumors show very high levels of dimeric PKM2, which in normal proliferating cells is in contrast mainly tetrameric. 6 Multiple signals such as growth factors, oncogenes or reactive oxygen species (ROS) were shown to destabilize the tetrameric form via a number of mechanisms including tyrosine phosphorylation, association with tyrosine phosphopeptides or oxidation. [7] [8] [9] In turn, decreased PKM2 activity correlates with increased proliferation. Although this can be partly explained by the diversion of glucose metabolites from catabolic to anabolic processes 10 and by the increased generation of anti-oxidant NADPH via the pentose phosphate pathway, 9 a consistent body of data points toward an independent role for PKM2 in the nucleus. Indeed, it was shown that both IL-3 and EGFR can induce PKM2 nuclear localization, correlating with cell proliferation. 11, 12 Nuclear PKM2 can associate with cSrc-phosphorylated β-catenin, and bind to the ccnd1 gene promoter activating cyclin D1 transcription. 12 Finally, PKM2 was recently proposed to be part of a "feed forward loop" enhancing the activity of hypoxia-inducible factor (HIF)-1, a key transcriptional regulator of both aerobic and anaerobic glycolysis. 13 Indeed, HIF-1 can activate pkm2 gene transcription, and PKM2 in turn interacts with the HIF-1a subunit and promotes trans-activation of HIF-1 target genes, thus enhancing cellular responses to oxygen deprivation or oncogene activation.
To investigate the functional significance of nuclear PKM2, Gao et al. 14 15 Moreover, STAT3 constitutive activity plays a key role in inflammation-induced cancer, by instating a feed forward loop entailing continuous production of the pro-inflammatory cytokine IL-6 and constitutive NFkB activation. 16 We have recently shown that constitutively active STAT3 induces chronically enhanced hif1a transcription that results in increased HIF-1a protein levels and triggers a metabolic switch toward aerobic glycolysis similar to the Warburg effect. 17, 18 STAT3 activation appears thus to participate in the recently proposed PKM2/HIF-1a positive feedback loop, 13 where oxygen deprivation or oncogenes lead to increased HIF-1a levels, HIF-1 induces pkm2 transcription, PKM2 enhances HIF-1 trans-activating power and activates STAT3 and finally activated STAT3 enhances HIF-1a expression (Fig. 1) . On the other hand, we have recently shown that constitutively active STAT3 can act as a first hit during the process of malignant transformation. 19 Aberrantly continuous STAT3 activation like that found in chronic inflammation might therefore sensitize cells to tumor transformation by initiating the above described positive feedback loop, leading to enhanced HIF-1a and PKM2 expression/activity. This would in turn support aerobic glycolysis, anabolic cell metabolism, cell survival and proliferation. Moreover, PKM2-mediated STAT3 phosphorylation may participate in the chronic STAT3 activation observed in highly glycolytic tumors of different origins. Although these findings shed some light on the correlation between the 20 Additionally, the simultaneous detection of both PKM2 and STAT3 on the mek5 promoter suggests that nuclear phosphorylation of STAT3 by PKM2 might even occur on the DNA, similar to what has been recently shown for STAT3 serine phosphorylation. 21 Small molecules enhancing PKM2 tetrameric activity have already been proposed as new therapeutic tools to compromise both the anabolic and the anti-oxidant functions of this protein. 9 The same compounds may also lead to the inhibition of PKM2-mediated STAT3 activation, potentially representing a useful therapeutic tool to help hitting the uncontrolled growth of those highly glycolytic tumors that display both STAT3 activation and dimeric PKM2.
